Key result
Autoantibodies targeting cardiac ion channels contribute to the pathogenesis of arrhythmias like atrial fibrillation and may offer opportunities for personalized antiarrhythmic therapies.
Autoantibodies against cardiac ion channels play a growing role in the pathogenesis of arrhythmias and may offer new targets for personalized antiarrhythmic therapies.
May guide autoantibody testing in refractory arrhythmias; leaves open whether targeted therapies improve outcomes.
Role of autoantibodies against atrial and ventricular ion channels in cardiac arrhythmias and their therapeutic potential. Autoantibodies targeting various cardiac ion channels can have inhibitory (−) and stimulatory (+) effects on depolarizing (purple: INa,peak and ICa,L) and repolarizing (green: IK) ion currents, contributing to pathogenesis of various cardiac arrhythmias, including atrial fibrillation (AF). Additionally, autoantibodies may offer opportunities to develop specific and personalized antiarrhythmic therapeutic approaches. For a detailed explanation, please refer to the text. INa,peak, peak sodium current; ICa,L, L-type-calcium current; IK, potassium current; QTc, corrected QT-interval; Tdp, Torsades de pointes tachycardia.
No takes yet. Share an insight, caveat, or question.
Fakuade et al. (2024) conducted a review in Cardiac arrhythmias. Autoantibodies against atrial and ventricular ion channels was evaluated. Autoantibodies targeting cardiac ion channels contribute to the pathogenesis of arrhythmias like atrial fibrillation and may offer opportunities for personalized antiarrhythmic therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: